BCLS Fund III Investments, LP 13D and 13G filings for Cidara Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 4:30 pm Sale | 2025-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BCLS Fund III Investments, LP | 0 0.000% | -3,020,990 (Position Closed) | Filing |
| 2025-11-14 4:30 pm Purchase | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | BCLS Fund III Investments, LP | 3,020,990 9.990% | 520,310 (+20.81%) | Filing |
| 2025-08-14 4:00 pm Purchase | 2025-06-30 | 13G | Cidara Therapeutics, Inc. CDTX | BCLS Fund III Investments, LP | 2,500,680 9.990% | 2,500,680 (New Position) | Filing |